for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eisai Co., Ltd

4523.T

Latest Trade

5,446.00JPY

Change

34.00(+0.63%)

Volume

824,200

Today's Range

5,398.00

 - 

5,514.00

52 Week Range

5,205.00

 - 

11,320.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,412.00
Open
5,430.00
Volume
824,200
3M AVG Volume
17.77
Today's High
5,514.00
Today's Low
5,398.00
52 Week High
11,320.00
52 Week Low
5,205.00
Shares Out (MIL)
286.58
Market Cap (MIL)
1,605,020.00
Forward P/E
20.15
Dividend (Yield %)
2.77

Next Event

Dividend For 4523.T - 80.0000 JPY

Latest Developments

More

U.S. FDA Says Announcing Project Orbis, An Initiative Of The FDA Oncology Center Of Excellence

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

Merck And Eisai Receive Third Breakthrough Therapy Designation From FDA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eisai Co., Ltd

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The other segment consists of pharmaceutical raw materials, logistics services and business services businesses.

Industry

Biotechnology & Drugs

Contact Info

Eisai Main Bldg., 4-6-10, Koishikawa

+81.3.38173700

https://www.eisai.co.jp/

Executive Leadership

Yasuhiko Kato

Chairman of the Board of Directors, Independent Director

Haruo Naito

Chief Executive Officer, Representative Executive Officer, Director

Ryohei Yanagi

Managing Executive Officer, Chief Financial Officer, Chief IR Officer

Hideki Hayashi

Representative Executive Officer, Chief Information Officer

Junichi Asatani

Executive Officer, Chief Compliance Officer

Key Stats

2.90 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.5K

2018

0.6K

2019

0.6K

2020(E)

0.7K
EPS (JPY)

2017

137.630

2018

181.180

2019

221.340

2020(E)

268.638
Price To Earnings (TTM)
21.32
Price To Sales (TTM)
2.49
Price To Book (MRQ)
2.55
Price To Cash Flow (TTM)
15.87
Total Debt To Equity (MRQ)
21.37
LT Debt To Equity (MRQ)
14.79
Return on Investment (TTM)
9.47
Return on Equity (TTM)
6.97

Latest News

Biogen scraps two late-stage Alzheimer's trials

Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Nikkei falls as financials drag; Eisai indicated to dive

Japan's Nikkei fell in choppy trade on Friday as financial stocks languished, reflecting more cautious U.S. monetary policy, while the drug sector tumbled after Eisai and Biogen said they will end their Alzheimer's drug trials.

Biogen, Eisai scrap Alzheimer drug trials

Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince

Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.

Biogen/Eisai Alzheimer's data suggests treatment effect related to drug

Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.

Nikkei rises as weak yen helps mood; Eisai soars

Japan's Nikkei rose on Friday as a weaker yen supported sentiment, with the pharmaceutical sector leading gains after a report that Eisai moved forward its mid-term profit goal by one year.

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)

Japan's Eisai gains U.S. approval for liver cancer treatment

The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.

Eisai shares fall 18 pct after release of Alzheimer drug test details

Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

Biogen's Alzheimer's drug succeeds in mid-stage trial

Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

BRIEF-Nichi-Iko Pharmaceutical says business and capital alliance with Eisai

* Says it forms business and capital alliance with Eisai Co Ltd

BRIEF-Anticancer Agent Lenvima Approved For Additional Indication Of Unresectable Hepatocellular Carcinoma In Japan

* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)

BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima

* EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE)

Merck, Eisai sign deal to further develop, sell Eisai cancer drug

Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many countries for two uses.

BRIEF-Morphotek Announces FDA Acceptance Of IND For Cancer Treatment

* MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up